Yes, just in the US, and only one of the sets of patents in the US. This one is about use of CRISPR-Cas9 in a eukaryotic environment specifically. Both parties have some other claims, and ultimately will have to cross-license each other for the technology to develop. Too bad such an important decision is being left to such a small group of university administrators who know very little about how best to grow the technology into successful therapies and technologies at scale!
